A Phase I Clinical Trial of an HPV Therapeutic Vaccine
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
real-time safety measurement of the combined administration of HPV vaccine and Candin® as measured by dose limiting toxicity as defined by adverse events; safety will be assessed at time of vaccination, 30 minutes post-injection, and daily for 7 days post injections.
immediately then up to 7 days post vaccinations
Mayumi Nakagawa, MD, PhD
University of Arkansas
United States: Food and Drug Administration
|University of Arkansas for Medical Sciences||Little Rock, Arkansas 72205|